Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q3 2025 · 10-Q
Revenue$0.00$0.00— vs Q3 2024 Net Income-$14.50M-$14.50MN/M vs Q3 2024 EPS Diluted-$0.38-$0.38N/M vs Q3 2024 Operating Income-$15,335,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,092,000— ended Mar 31, 2025 · filed May 14, 2025 · 44 d after period end